Alexandur Mazur

  • Citations Per Year
Learn More
BACKGROUND In 2010 the US FDA approved dabigatran, the first new anticoagulant for stroke prevention in non-valvular atrial fibrillation (AF) since 1954. To date there is little data that reflects the experiences and perceptions of real-world patients with dabigatran. The abundance of Internet-based discussion forums and support groups related to AF or(More)
It is assumed by the author that the pre-addiction personality as well as probable events which could directly precede excessive drinking (understood even as a main cause) are, in the practice of a therapist, less important than the fact that a person who abuses alcohol will sooner or later complicate his or her life and arising difficulties will motivate(More)
  • 1